BRIEF—First generic Remodulin approved in China

China has approved the country's first generic version of USA-based lung specialist United Therapeutics' Remodulin (treprostinil sodium), a treatment for the rare disease pulmonary hypertension.

The supplier of the Remodulin generic is Zhaoke Pharm, a Hefei, Anhui province-based subsidiary of the Hong Kong pharma Lee's Pharmaceutical.

In 2010, Lee's in-licensed Remodulin for the Chinese market and gained its China New Drug Application (NDA) approval in 2014 with a price tag as high as 99,900 renminbi per vial (200mg/20ml) ($14,112).